




Healthcare Industry News: Magnetic Resonance Imaging
News Release - February 28, 2006
Siemens and Haifu Collaborate to Advance Tumor Treatment
New MRI-Guided HIFU Improves Ultrasound TherapyMALVERN, Pa.--(HSMN NewsFeed)--Feb. 28, 2006--Siemens Medical Solutions and Chongqing Haifu (Haifu) Technology Co., Ltd. today announced a collaboration to develop a Magnetic Resonance Imaging (MRI) guided high-intensity focused ultrasound (HIFU) therapy system. Expanding Siemens' solutions offering, this technology should provide excellent diagnostic accuracy and innovative image-guided therapy options. The main applications of this system will focus on women's health treatments including benign uterine fibroids and cancer, as well as malignant and benign tumors of the liver, kidney, pancreas and bone.
The combination of MRI and HIFU enables improved visualization of tumor morphology and more precise thermal dose control, designed to reduce current treatment times. Further developments involve MRI applications for diagnosis, therapy planning and outcome assessment. Patient treatment will be performed on a special HIFU patient bed inside the bore of Siemens' MRI scanners. For example, the MAGNETOM Espree(TM) with TimŽ (Total imaging matrix) technology is well suited for the treatment since it provides the HIFU beam excellent access to the tumor location as it offers maximum freedom for patient positioning. Sonication of uterine fibroids is expected to take considerably less time than with traditional technology.
"We are excited to partner with Siemens Medical Solutions to offer advanced HIFU technology, improving treatment options to our customers and the medical industry," said Professor Zhibiao Wang, president, Haifu. "Haifu has great international success with ultrasound-guided HIFU treatment and we believe using MRI as a guided imaging modality is the future of this technology, providing a new direction to advance tumor treatment."
HIFU technology overcomes traditional limitations, as it can visualize and treat large tissue volumes in a short matter of time. Since the 1950s, HIFU has been proposed as a therapeutic method. Today, it is used daily in hospitals around the world, with ultrasound technology commonly used as the guided imaging modality. Positive clinical outcomes involving HIFU have been documented in more than 25 international peer reviewed publications.
Chongqing Haifu (Haifu) Technology Co. Ltd. is a manufacturer of medical devices specialized in developing Therapeutic Ultrasound Systems based in Chongqing, PRC, and founded in 1999. The company employs 200 people. Research and Development, Production, Sales & Marketing and the International Department are all located in house where they focus on research, manufacturing and clinical applications development. The company has its own Clinical Center for Tumor Therapy and cooperates with the Institute of Ultrasound Engineering in Medicine at Chongqing University of Medical Sciences. After 17 years of research, Haifu has developed and produced a series of products such as the JC Extracorporeal Focused Ultrasound Tumor Therapy System or the CZF Therapeutic System for Gynaecological Diseases (Seapostar). More information about Haifu can be found at http://www.haifu.com.cn.
Siemens Medical Solutions of Siemens AG (NYSE:SI ) with headquarters in Malvern, Pennsylvania, and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and group profit of 976 million EUR for fiscal 2005. More information can be obtained by visiting www.usa.siemens.com/medical-pressroom.
Source: Siemens Medical Solutions
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.